Donated plasma is used to make treatments for dozens of serious medical conditions, from bleeding disorders and immune deficiencies to severe burns and trauma. It takes roughly 130 individual plasma donations just to produce one year’s worth of immune therapy for a single patient with a primary immunodeficiency disorder. That gives you a sense of the scale: demand for donated plasma is enormous, and every donation feeds into a supply chain that produces multiple life-saving products.
Plasma itself is about 92% water. The remaining 7% is proteins, including albumin, clotting factors, and infection-fighting antibodies called immunoglobulins. These proteins are the valuable part. After collection, manufacturers separate plasma into its individual protein components through a process called fractionation, and each component becomes a different medication.
Immune Therapy for People Who Can’t Fight Infections
One of the biggest uses of donated plasma is producing immunoglobulin, a concentrated dose of antibodies extracted from thousands of pooled donations. These antibodies are given intravenously (a treatment called IVIG) to people whose immune systems don’t work properly on their own. That includes people with primary immunodeficiency disorders, a group of genetic conditions where the body simply doesn’t produce enough antibodies. Without regular infusions, even a common cold can become dangerous for these patients.
IVIG is also used to manage autoimmune conditions where the immune system attacks the body’s own tissues. Doctors use it for conditions like lupus, vasculitis, myositis, Kawasaki disease, and Sjögren’s syndrome, among others. It can also help patients whose immune systems have been suppressed by other medical treatments, such as certain cancer therapies. Because each patient needs ongoing infusions, and each course of treatment draws from a large pool of donations, immunoglobulin production consumes a significant share of the global plasma supply.
Clotting Factors for Hemophilia
People with hemophilia are missing specific proteins that allow blood to clot normally. Without treatment, even minor injuries can cause prolonged, dangerous bleeding. The standard treatment is to replace the missing clotting factor through an injection into a vein. One major source of these clotting factors is donated plasma.
To make plasma-derived clotting factor concentrates, manufacturers collect plasma from many donors, pool it, and run it through multiple separation steps to isolate the specific proteins needed. Factor VIII is used for hemophilia A, and Factor IX for hemophilia B. The finished product is freeze-dried, tested, and treated through several virus-killing steps before packaging. Synthetic (recombinant) versions also exist, but plasma-derived concentrates remain an important part of the treatment landscape, particularly in parts of the world where recombinant products are less available.
Albumin for Burns, Shock, and Liver Disease
Albumin is the most abundant protein in plasma. Its main job is keeping fluid balanced between your bloodstream and surrounding tissues, essentially preventing liquid from leaking out of blood vessels where it doesn’t belong. When someone suffers severe burns, major surgery, or acute blood loss, albumin levels drop sharply, and fluid balance falls apart. Giving purified albumin helps restore blood volume and stabilize blood pressure.
Beyond emergency situations, albumin is used during heart bypass surgery as a priming fluid, and it treats conditions involving dangerously low protein levels in the blood. Patients with severe kidney disease who develop swelling, or those with adult respiratory distress syndrome who have fluid buildup in the lungs, may receive albumin alongside other treatments. It’s also used to treat a condition called hemolytic disease of the newborn, where a baby’s red blood cells are being destroyed.
Emergency Trauma and Massive Blood Loss
When someone arrives at a trauma center with life-threatening bleeding, plasma is one of the first things they receive. Trauma teams transfuse plasma alongside red blood cells in roughly equal ratios to replace both the oxygen-carrying capacity and the clotting ability of lost blood. Without plasma, a patient receiving only red blood cells would continue bleeding because their blood would lack the proteins needed to form clots.
Speed matters enormously in these situations. Trauma centers keep thawed plasma on hand so it’s ready for immediate use, typically at least eight units of universal-type plasma available for release the moment a massive transfusion is activated. Additional units are expected within 15 minutes. Plasma is frozen within 24 hours of donation to preserve clotting factors and can be stored for up to one year at minus 18 degrees Celsius or colder. This long shelf life is part of what makes plasma such a reliable resource for hospitals.
Treatment for Rare Genetic Conditions
Some people are born with a deficiency in a protein called alpha-1 antitrypsin, which normally protects the lungs from damage. Without enough of it, they develop emphysema, often at a younger age than typical. The treatment is called augmentation therapy: purified alpha-1 antitrypsin, collected from blood donors, is delivered through an IV on a regular schedule. It can’t reverse lung damage that’s already occurred, but it slows the progression of the disease.
This is one example of a broader category. Several rare conditions are treated with specific proteins purified from donated plasma. Because these diseases affect relatively small numbers of people, the treatments don’t get the same public attention as something like trauma care, but for the individuals who depend on them, a steady plasma supply is the difference between manageable health and serious decline.
How Plasma Becomes Medicine
The process of turning raw plasma into finished medications is called fractionation, and it dates back to a method developed in the 1940s. The core technique uses cold temperatures and ethanol (alcohol) to gradually separate proteins based on their physical properties. Albumin and immunoglobulins were the first products isolated this way. Clotting factors like Factor VIII are separated by slowly thawing frozen plasma at cold temperatures to produce a substance called cryoprecipitate, which is rich in clotting proteins.
Modern manufacturing has added large-scale chromatography, a more precise filtering technique, to improve the purity and yield of individual proteins. Coagulation factors, protease inhibitors, and other specialized proteins are now extracted using these methods. Every batch also undergoes multiple virus-killing steps: heat treatment at 60 degrees Celsius for 10 hours, chemical treatments to destroy the outer shells of viruses, and nanofiltration through filters with pores measured in billionths of a meter. These layered safety steps are why plasma-derived products have an excellent safety record.
Convalescent Plasma Is Different
You may have heard about convalescent plasma during the COVID-19 pandemic. This is a separate use from everything described above. Convalescent plasma comes from people who have recovered from a specific infection and developed high levels of antibodies against it. Rather than being fractionated into components, it’s transfused directly to patients fighting that same infection, delivering a concentrated dose of relevant antibodies.
This approach has been used historically when new diseases appear and no vaccines or treatments exist yet. It’s a stopgap measure, not a routine therapy. Standard plasma donation, by contrast, feeds into the large-scale manufacturing process that produces the immunoglobulins, clotting factors, albumin, and other protein therapies that patients depend on year-round.